Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. Among authors: de alava e. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
Prognostic impact of P53 status in Ewing sarcoma.
de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindán FJ, Healey JH, Ladanyi M. de Alava E, et al. Cancer. 2000 Aug 15;89(4):783-92. Cancer. 2000. PMID: 10951341
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Abad M, Domínguez S, Florián J, Llorca C, Méndez M, Godes M, Cubedo R, Murias A, Batista N, García MJ, Caballero R, de Alava E. Martín M, et al. Among authors: de alava e. Breast Cancer Res Treat. 2010 Aug;123(1):149-57. doi: 10.1007/s10549-009-0663-z. Breast Cancer Res Treat. 2010. PMID: 20037779 Clinical Trial.
A new multidisciplinary Spanish Working Group on Cancer Biomarkers: presentation and aims.
Colomer R, Garrido P, de Álava E, García Alfonso P, Palacios J, Ariza A; Multidisciplinary Working Group on Cancer Biomarkers of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Colomer R, et al. Among authors: de alava e. Clin Transl Oncol. 2012 May;14(5):323-4. doi: 10.1007/s12094-012-0803-5. Clin Transl Oncol. 2012. PMID: 22551536 No abstract available.
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E, de Torres C. Mora J, et al. Among authors: de alava e, de torres c. Br J Cancer. 2017 Sep 5;117(6):767-774. doi: 10.1038/bjc.2017.252. Epub 2017 Aug 8. Br J Cancer. 2017. PMID: 28787430 Free PMC article. Clinical Trial.
[Clinical challenges and implications of intratumor heterogeneity].
Palacios J, Matías-Guiu X, Rodríguez-Peralto JL, de Álava E, López JI. Palacios J, et al. Among authors: de alava e. Rev Esp Patol. 2019 Oct-Dec;52(4):234-241. doi: 10.1016/j.patol.2019.04.004. Epub 2019 Jun 6. Rev Esp Patol. 2019. PMID: 31530406 Review. Spanish.
215 results